Baicalin improves the inflammatory response of RA-FLS by targeting the circ_0000734/miR-197-5p/IKBKB axis
-
By
-
Yanqiu Sun
-
Jian Liu
-
Mingyu He
-
Xiaolu Chen
-
May 28, 2026
-
Clinical Scorecard: Baicalin Modulates Inflammation in RA-Fibroblast-like Synoviocytes via the circ_0000734/miR-197-5p/IKBKB Pathway
At a Glance
| Category | Detail |
|---|
| Condition | Rheumatoid Arthritis (RA) |
| Key Mechanisms | circ_0000734/miR-197-5p/IKBKB pathway |
| Target Population | Patients with Rheumatoid Arthritis |
| Care Setting | Clinical research setting |
Key Highlights
- circ_0000734 is highly expressed in RA patients and correlates with disease activity indicators.
- Baicalin treatment downregulates circ_0000734 and inhibits NF-κB pathway activation.
- Overexpression of miR-197-5p reverses the effects of circ_0000734 on RA-FLS cell viability.
Guideline-Based Recommendations
Diagnosis
- Evaluate circ_0000734 expression in PBMCs as a potential biomarker for RA.
Management
- Consider baicalin as a therapeutic agent to modulate inflammation in RA.
Monitoring & Follow-up
- Monitor disease activity indicators such as RF, anti-CCP, CRP, ESR, and DAS28 scores.
Risks
- Existing RA treatments may have adverse reactions and drug resistance.
Patient & Prescribing Data
Patients diagnosed with Rheumatoid Arthritis
Baicalin may improve inflammatory responses by targeting circ_0000734.
Clinical Best Practices
- Utilize qRT-PCR to assess circ_0000734 expression levels.
- Implement dual-luciferase reporter assays to confirm regulatory relationships.
Related Resources & Content
